Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: CompuCyte

This article was originally published in The Gray Sheet

Executive Summary

CompuCyte: Receives $2 mil. equity investment from San Diego-based healthcare alliance American Healthcare Systems, bringing total investments in Cambridge, Massachusetts-based CompuCyte to $8.6 mil. CompuCyte's first product, the Pathfinder system, "attaches to a lab technologists' microscope and displays on a computer monitor all the areas of a Pap smear slide that have been examined -- as well as areas that were missed," helping to avoid "potentially fatal mistakes that may result from incomplete and/or inadequate screening of Pap smears," the firm says. Currently undergoing tests, the device is expected to become available to hospitals and labs throughout the U.S. this fall...

You may also be interested in...



Performance Issues With CDC’s COVID-19 Assay Reagents Slows Rollout Of Test Kits To US States

A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a CDC says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.

Orphan Indications In Medicare: Inspector General Will Examine Top-Selling Drugs

OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.

Basilea Stresses Derazantinib's FGFR Kinase Differentiation

Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.

 

UsernamePublicRestriction

Register

MT004476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel